Ost-müük 10x Genomics, Inc. - TXG CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.14 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 51.97 |
Avatud* | 53.18 |
Aastane muutus* | -28.68% |
Päeva ulatus* | 53.18 - 56.09 |
52 nädala ulatus | 23.81-83.34 |
Keskmine maht (10 päeva) | 754.85K |
Keskmine maht (3 kuud) | 21.21M |
Turukapitalisatsioon | 6.00B |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 115.36M |
Tulu | 516.41M |
EPS | -1.46 |
Dividendid (% kasumist) | N/A |
Beeta | 1.74 |
Järgmine tuluaruande kuupäev | May 2, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 55.73 | 3.30 | 6.29% | 52.43 | 56.16 | 52.01 |
Mar 30, 2023 | 51.97 | 0.76 | 1.48% | 51.21 | 52.32 | 51.07 |
Mar 29, 2023 | 50.69 | 1.41 | 2.86% | 49.28 | 50.98 | 49.00 |
Mar 28, 2023 | 48.81 | -0.45 | -0.91% | 49.26 | 49.42 | 48.27 |
Mar 27, 2023 | 49.70 | -0.68 | -1.35% | 50.38 | 51.52 | 49.29 |
Mar 24, 2023 | 50.12 | 2.16 | 4.50% | 47.96 | 50.30 | 47.65 |
Mar 23, 2023 | 48.97 | 0.03 | 0.06% | 48.94 | 51.49 | 48.48 |
Mar 22, 2023 | 48.69 | -1.39 | -2.78% | 50.08 | 51.08 | 48.61 |
Mar 21, 2023 | 50.03 | 1.83 | 3.80% | 48.20 | 50.25 | 47.91 |
Mar 20, 2023 | 47.76 | 0.30 | 0.63% | 47.46 | 48.56 | 46.76 |
Mar 17, 2023 | 48.08 | -1.09 | -2.22% | 49.17 | 49.71 | 47.66 |
Mar 16, 2023 | 50.25 | 2.49 | 5.21% | 47.76 | 50.90 | 47.60 |
Mar 15, 2023 | 48.54 | 1.45 | 3.08% | 47.09 | 49.32 | 47.08 |
Mar 14, 2023 | 48.63 | 0.07 | 0.14% | 48.56 | 49.52 | 48.06 |
Mar 13, 2023 | 47.44 | 3.47 | 7.89% | 43.97 | 49.32 | 43.97 |
Mar 10, 2023 | 44.93 | -1.55 | -3.33% | 46.48 | 46.49 | 43.15 |
Mar 9, 2023 | 47.00 | -1.65 | -3.39% | 48.65 | 49.98 | 46.93 |
Mar 8, 2023 | 48.95 | 1.16 | 2.43% | 47.79 | 49.49 | 47.24 |
Mar 7, 2023 | 48.16 | 0.10 | 0.21% | 48.06 | 49.75 | 47.48 |
Mar 6, 2023 | 48.39 | -2.30 | -4.54% | 50.69 | 50.80 | 48.13 |
10x Genomics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Tulu | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Kulud, Kokku | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Brutokasum | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Kogu tegevuskulu | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Müük/Üldine/admin kulud, kokku | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Uuringud ja arendus | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Tulud majandustegevusest | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Intressitulud (kulu), muud tulud, neto | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Muud, neto | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Netotulu enne makse | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Netotulu pärast makse | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Netotulu enne erikulusid | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Erakorralised kulud kokku | |||||
Netotulu | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Arvestatav tulu, v a erikulud | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Arvestatav tulu, koos erikuludega | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Jaotamisele kuuluv netotulu | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Keskmine jaotamisele kuuluv aktsia kohta | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
Jaotatav EPS, v a erakorralised kulud | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
Jaotamisele kuuluv normaal-EPS | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Ootamatud kulutused (tulu) | 0 | 0 | 4.121 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Tulu | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Kulud, Kokku | 36.827 | 30.377 | 27.704 | 25.478 | 27.598 |
Brutokasum | 119.405 | 100.695 | 86.905 | 89.018 | 115.932 |
Kogu tegevuskulu | 179.328 | 171.068 | 177.726 | 156.231 | 159.36 |
Müük/Üldine/admin kulud, kokku | 78.887 | 73.401 | 79.337 | 66.675 | 69.877 |
Uuringud ja arendus | 63.614 | 67.29 | 70.685 | 64.078 | 61.885 |
Ootamatud kulutused (tulu) | 0 | 0 | |||
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
Tulud majandustegevusest | -23.096 | -39.996 | -63.117 | -41.735 | -15.83 |
Intressitulud (kulu), muud tulud, neto | 2.69 | 1.911 | 1.129 | 0.441 | -0.168 |
Muud, neto | 3.995 | -1.95 | -1.843 | -0.4 | 0.005 |
Netotulu enne makse | -16.411 | -40.035 | -63.831 | -41.694 | -15.993 |
Netotulu pärast makse | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netotulu enne erikulusid | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netotulu | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Arvestatav tulu, v a erikulud | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Arvestatav tulu, koos erikuludega | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Jaotamisele kuuluv netotulu | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Keskmine jaotamisele kuuluv aktsia kohta | 114.767 | 114.112 | 113.575 | 112.966 | 111.913 |
Jaotatav EPS, v a erakorralised kulud | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 747.591 | 774.366 | 480.84 | 106.236 | 68.107 |
Raha ja lühiajalised investeeringud | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Raha ja ekvivalendid | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Laekumata arved, neto | 85.254 | 51.208 | 33.371 | 29.566 | 13.341 |
Accounts Receivable - Trade, Net | 85.254 | 51.208 | 33.371 | 28.088 | 13.341 |
Total Inventory | 59.966 | 29.959 | 15.27 | 8.57 | 4.838 |
Prepaid Expenses | 13.896 | 13.029 | 8.033 | 3.02 | 2.071 |
Total Assets | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Property/Plant/Equipment, Total - Net | 230.41 | 119.823 | 48.821 | 11.127 | 6.925 |
Property/Plant/Equipment, Total - Gross | 279.431 | 150.325 | 67.876 | 25.21 | 17.958 |
Accumulated Depreciation, Total | -49.021 | -30.502 | -19.055 | -14.083 | -11.033 |
Other Long Term Assets, Total | 10.917 | 12.798 | 76.262 | 6.947 | 0.577 |
Total Current Liabilities | 110.357 | 118.126 | 63.049 | 32.362 | 22.141 |
Accounts Payable | 17.351 | 4.709 | 13.028 | 8.792 | 5.443 |
Accrued Expenses | 75.821 | 92.326 | 30.035 | 12.118 | 8.959 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | 4.224 | |
Other Current Liabilities, Total | 17.185 | 21.091 | 10.104 | 7.265 | 3.515 |
Total Liabilities | 201.258 | 190.269 | 185.84 | 101.053 | 29.704 |
Total Long Term Debt | 0 | 0 | 19.837 | 25.489 | 6.335 |
Long Term Debt | 0 | 19.837 | 25.489 | 6.335 | |
Other Liabilities, Total | 90.901 | 72.143 | 102.954 | 43.202 | 1.228 |
Total Equity | 817.568 | 739.072 | 420.083 | 23.257 | 45.905 |
Redeemable Preferred Stock | 0 | 243.244 | 158.414 | ||
Common Stock | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 1680.86 | 1544.22 | 682.494 | 11.165 | 6.136 |
Retained Earnings (Accumulated Deficit) | -863.321 | -805.098 | -262.367 | -231.116 | -118.631 |
Other Equity, Total | 0.022 | -0.05 | -0.046 | -0.037 | -0.015 |
Total Liabilities & Shareholders’ Equity | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Total Common Shares Outstanding | 112.515 | 108.486 | 96.2416 | 93.8497 | 93.8497 |
Other Current Assets, Total | 1.028 | 16.567 | |||
Intangibles, Net | 25.397 | 22.354 | |||
Goodwill, Net | 4.511 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 697.335 | 747.591 | 744.104 | 757.174 | 745.716 |
Raha ja lühiajalised investeeringud | 539.323 | 587.447 | 600.44 | 621.958 | 617.195 |
Raha ja ekvivalendid | 312.487 | 587.447 | 600.44 | 621.958 | 617.195 |
Laekumata arved, neto | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Accounts Receivable - Trade, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Total Inventory | 63.697 | 59.966 | 51.141 | 44.087 | 38.507 |
Prepaid Expenses | 17.762 | 13.896 | 14.065 | 13.298 | 14.442 |
Other Current Assets, Total | 0.027 | 1.028 | 0.028 | 18.151 | 18.164 |
Total Assets | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Property/Plant/Equipment, Total - Net | 265.88 | 230.41 | 203.304 | 176.454 | 163.666 |
Property/Plant/Equipment, Total - Gross | 279.431 | 247.698 | 215.665 | 198.415 | |
Accumulated Depreciation, Total | -49.021 | -44.394 | -39.211 | -34.749 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 24.764 | 25.397 | 26.041 | 26.693 | 27.342 |
Other Long Term Assets, Total | 10.761 | 10.917 | 12.612 | 12.747 | 12.798 |
Total Current Liabilities | 94.446 | 110.357 | 100.375 | 113.126 | 120.549 |
Accounts Payable | 18.956 | 17.351 | 17.037 | 16.181 | 15.578 |
Accrued Expenses | 59.913 | 75.821 | 69.92 | 85.598 | 95.307 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.577 | 17.185 | 13.418 | 11.347 | 9.664 |
Total Liabilities | 196.566 | 201.258 | 190.351 | 192.993 | 201.573 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 102.12 | 90.901 | 89.976 | 79.867 | 81.024 |
Total Equity | 806.685 | 817.568 | 800.221 | 784.586 | 752.46 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1714.86 | 1680.86 | 1644.9 | 1612.23 | 1569.06 |
Retained Earnings (Accumulated Deficit) | -905.734 | -863.321 | -844.872 | -827.701 | -816.649 |
Other Equity, Total | -2.443 | 0.022 | 0.194 | 0.058 | 0.048 |
Total Liabilities & Shareholders’ Equity | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Total Common Shares Outstanding | 113.276 | 112.515 | 111.537 | 110.74 | 109.589 |
Lühiajalised investeeringud | 226.836 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -58.223 | -542.731 | -31.251 | -112.485 | -18.762 |
Raha majandustegevusest | -21.373 | -217.898 | 34.627 | -76.409 | -10.699 |
Raha majandustegevusest | 21.118 | 14.012 | 7.066 | 3.905 | 4.305 |
Mittelikviidsed varad | 103.177 | 361.202 | 14.048 | 4.156 | 1.81 |
Cash Taxes Paid | 8.66 | 0.28 | -0.022 | -0.006 | 0 |
Makstud intressid | 1.222 | 1.67 | 2.25 | 1.824 | 0.658 |
Muutused tööjõus | -87.445 | -50.381 | 44.764 | 28.015 | 1.948 |
Tulu investeeringutelt | -106.729 | -38.394 | -42.767 | -6.709 | -3.756 |
Kapitalikulutused | -101.278 | -38.394 | -42.767 | -6.709 | -3.756 |
Rahavood investeeringutelt | 35.297 | 468.906 | 414.59 | 105.367 | 20.583 |
Rahavoogudesse investeerimine | -5.028 | -5.848 | 0 | 0 | |
Aktsiate emiteerimine (tagasiost), neto | 40.325 | 506.01 | 414.59 | 86.628 | 20.976 |
Laenu väljastamine (kustutamine), neto | 0 | -31.256 | 0 | 18.739 | -0.393 |
Muutused valuutakursside kõikumisest | 0.234 | -0.463 | -0.045 | -0.018 | -0.014 |
Rahaline kogumuutus | -92.571 | 212.151 | 406.405 | 22.231 | 6.114 |
Muud rahavood investeeringutelt, kokku | -5.451 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -42.413 | -58.223 | -39.774 | -22.603 | -11.551 |
Cash From Operating Activities | -20.802 | -21.373 | -27.178 | -0.962 | -4.082 |
Cash From Operating Activities | 6.191 | 21.118 | 15.337 | 9.641 | 4.752 |
Non-Cash Items | 28.014 | 103.177 | 74.717 | 47.188 | 17.922 |
Cash Taxes Paid | 2.9 | 8.66 | 8.318 | 7.838 | 6.822 |
Cash Interest Paid | 0.841 | 1.222 | 1.222 | 1.222 | 1.222 |
Changes in Working Capital | -12.594 | -87.445 | -77.458 | -35.188 | -15.205 |
Cash From Investing Activities | -257.558 | -106.729 | -79.111 | -58.884 | -44.316 |
Capital Expenditures | -28.136 | -101.278 | -73.66 | -53.433 | -38.865 |
Other Investing Cash Flow Items, Total | -229.422 | -5.451 | -5.451 | -5.451 | -5.451 |
Cash From Financing Activities | 2.417 | 35.297 | 26.394 | 19.711 | 3.518 |
Financing Cash Flow Items | -5.409 | -5.028 | -5.028 | -5.028 | -5.028 |
Issuance (Retirement) of Stock, Net | 7.826 | 40.325 | 31.422 | 24.739 | 8.546 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Foreign Exchange Effects | -0.018 | 0.234 | 0.316 | 0.199 | 0.193 |
Net Change in Cash | -275.961 | -92.571 | -79.579 | -39.936 | -44.687 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 9.4813 | 9210082 | -415196 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.8556 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6523 | 8404774 | 145652 | 2022-12-31 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.3511 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.4437 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3422 | 4217954 | 207975 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3012 | 3206783 | -184394 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.2549 | 3161803 | -518131 | 2022-12-31 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.0939 | 3005427 | 0 | 2022-12-31 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.6231 | 2548100 | -57577 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2421 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1979 | 2135038 | -17833 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.018 | 1960300 | -337642 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.507 | 1463901 | 1108820 | 2022-12-31 | HIGH |
Brown Capital Management, LLC | Investment Advisor | 1.4964 | 1453630 | -161463 | 2022-12-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 1.3985 | 1358528 | -1145000 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3854 | 1345749 | -18168 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3601 | 1321234 | 63324 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.2491 | 1213394 | 999487 | 2022-12-31 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.2158 | 1180996 | 27291 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
Ettevõttest 10x Genomics, Inc.
10x Genomics, Inc. on bioteaduste tehnoloogiaettevõte. Ettevõtte integreeritud lahenduste hulka kuuluvad bioloogiliste süsteemide analüüsimiseks vajalikud instrumendid, tarbekaubad ja tarkvara. Ettevõtte toodete hulka kuuluvad Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Gene Expression, Spatial Multiomics ja Targeted Gene Expression. Seadmete hulka kuuluvad Chromium X-seeria, Chromium Connect ja Chromium Controller. Tema tehnoloogia Next GEM tehnoloogia, mis hõlmab kiibid ja ühilduvad reaktiivid, mida pakutakse ühe raku tooteportfelli jaoks. Tarbekaupade portfelli kuuluvad mikrofluidilised kiibid, slaidid, reaktiivid ja muud tarbekaubad nii Visium- kui ka Chromium-lahenduste jaoks. Ettevõtte rakenduste hulka kuuluvad CRISPR (clustered regular interspaced short palindromic repeats) skriining, multioomiline tsütomeetria ja immuunretseptorite kaardistamine.
Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com